CINQAIR is the only anti–IL-5 that offers personalized dosing
HCP=healthcare professional; IL-5=interleukin-5.
REFERENCES: 1. CINQAIR Prescribing Information. West Chester, PA. Teva Respiratory, LLC. 2. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355-366. 3. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789-798. 4. Data on file (clinical study report: a 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab [3.0 mg/kg] treatment in patients with moderate to severe asthma. Study C38072/3084). Parsippany, NJ. Teva Respiratory, LLC. February 2015. 5. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799-810.